Meda, a Swedish specialty-pharmaceutical company, agreed to acquire MedPointe, another specialty pharma in Somerset, N.J., for roughly $820 million in cash and stock. Meda’s release — and be careful, as it’s a little difficult to slog through even though it’s (ostensibly) written in English — is here (PDF). (One hint for the baffled: “MUSD” stands for “millions of U.S. dollars.”)

MedPointe was backed by several private-equity firms — the Carlyle Group, the Cypress Group and Ferrer Freeman & Co. — as well as traditional venture capitalists Frazier Healthcare Ventures. These four investors will all become shareholders in Meda.

Meda will pay MedPointe’s shareholders $520 million in cash and issue them 17.5 million Meda shares as well. At the stock’s recent close of 115 Swedish krona on the Stockholm Stock Exchange, the stock portion of the deal is worth roughly $300 million U.S. dollars.

MedPointe will become Meda’s main U.S. affiliate. Its net sales were $252 million in 2006, 23 percent higher than the previous year. MedPointe sells antihistamine nasal sprays, epilepsy drugs, muscle relaxants and cough suppressants. It has 710 employees, approximately 500 of which are in sales and marketing.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.